Secondary Hyperparathyroidism (SHPT) Features

The Medical Minute New Type of PTH Testing May Help Predict HD Patient Death Risk

New Type of PTH Testing May Help Predict HD Patient Death Risk

A new study suggests that non-oxidized, biologically active PTH testing may help determine mortality risk in hemodialysis patients.

CME Articles

Thyroid Functional Disease in Dialysis Patients

Emerging data suggest that thyroid hormone deficiency may be associated with 
greater cardiovascular morbidity and mortality in this population.

World Literature Review

Ethanol May Ease Secondary Hyperparathyroidism Post-Tx

Percutaneous ethanol injection therapy (PEIT) is a useful and safe treatment alternative for patients with persistent post-transplant secondary hyperparathyroidism, researchers in Argentina report.

Latest Secondary Hyperparathyroidism (SHPT) News

Hemodialysis Patients Benefit More from Oral than IV Vitamin D

Hemodialysis Patients Benefit More from Oral than IV Vitamin D

Switching from intravenous to oral alfacalcidol resulted in greater PTH suppression in patients with secondary hyperparathyroidism.

Cinacalcet's Cardiovascular Benefits Modest in Dialysis Patients

Researchers find a 'nominally significant' decrease in the risk of a composite outcome of death and nonfatal major cardiovascular events.

Give Priority to Phosphate Control, Researchers Conclude

Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.

CKD Complications Linked to BMI, Waist Size

Greater body mass index and waist circumference increases risk of secondary hyperparathyroidism, hyperphosphatemia, and hypertension.

High, Low PTH Raises Hypercalcemia Risk

NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.

Novel Formulation Corrects Vitamin D, Lowers iPTH

NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.

SHPT Linked to Vitamin D Deficiency in CKD Patients

NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.

Labs May Vary in iPTH Measurements

NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.

CKD Patients May Need Higher 25D Levels

NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Calcitriol as Effective as Vitamin D Analogues, but Cheaper

NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Paricalcitol Superior for Lowering iPTH

The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.

Antioxidant Nutraceutical May Help Treat Secondary Hyperparathyroidism

LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.

Inpatient Savings May Offset Cinacalcet Costs

LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation's Spring Clinical Meetings.

Paricalcitol Found Better for Lowering PTH

VANCOUVER, B.C.—Paricalcitol is more effective than ergocalciferol at lowering parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) stages 3 and 4 and who have vitamin D deficiency and secondary hyperparathyroidism, data suggest.

Cinacalcet May Reduce ESA Use

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.